GNE myopathy is a rare, recessively inherited, early adult-onset myopathy, characterized by distal and proximal muscle degeneration which often spares the quadriceps. It is caused by mutations in the UDP-N-acetylglucosamine 2-epimerase/Nacetylmannosamine kinase gene (GNE). This study aimed to identify the diseasecausing mutation in a three-generation Han-Chinese family with members who have been diagnosed with myopathy. A homozygous missense mutation, c.1627G>A (p.V543M) in the GNE gene co-segregates with the myopathy present in this family.
| INTRODUCTION
GNE myopathy, also referred to as Nonoaka myopathy, was first described as distal myopathy having rimmed vacuoles (DMRV) in 1981 in Japanese patients, later called "hereditary inclusion body myopathy (HIBM)" or "inclusion body myopathy 2 (IBM2)". It is a rare, recessively inherited, early adult-onset myopathy. 1 It is typically characterized by slow progression that preferentially affects the tibialis anterior muscles, commonly spares the quadriceps femoris muscles and gradually spreads to other muscles. 2, 3 GNE myopathy occurs worldwide. The prevalence ranges from 1/1 000 000 to 21/ 1 000 000, although it may be underestimated as many patients escape diagnosis. 1, 4 It has a higher prevalence in Middle Eastern
Jews and Japanese. GNE myopathy is caused by the mutations in the UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene (GNE), which encodes the bifunctional enzyme catalysing the first two rate-limiting steps in sialic acid biosynthesis. 5 In this study, targeted exome capture and high-throughput sequencing of 411 known genes involved in neuromuscular disorders were performed to identify genetic causes of an autosomal recessive GNE myopathy in a three-generation Han-Chinese pedigree. 6 A homozygous missense mutation, c.1627G>A (p.V543M), in the GNE gene was found to co-segregate with the GNE myopathy present in this family.
| MATERIALS AND METHODS

| Participators and clinical evaluation
A 13-person, three-generation Han-Chinese pedigree was recruited at the Third Xiangya Hospital, Central South University, Changsha, Hunan, China ( Figure 1A ). Clinical data, and peripheral blood samples were obtained from 9 members, including 2 affected (II:3 and II:5) and 7 unaffected individuals (I:1, I:2 
| Variant analysis and direct Sanger sequencing
Genomic DNA (gDNA) was isolated from peripheral blood using the phenol-chloroform extraction method. 
| GNE mutation screening
A prioritization scheme similar to those described in recent studies was used to identify proband pathogenic variants. Figure 1D ).
| Bioinformatics analysis of the mutation
Valine at position 543 (p.Val543) is conserved across different species ( Figure 3) . Based on the predicted values of several functional prediction software programs, including PolyPhen-2, SIFT, MutPred2
and MutationTaster, c.1627G>A (p.V543M) in the GNE gene is deemed "severe", that is protein damaging. The predicted scores and results of functional prediction software programs appear in Table 2 .
| DISCUSSION
The GNE gene, mapped to chromosome 9p13.3, spans 62.6 kb and contains 13 exons. 1 Eight different GNE mRNA splice variants encode multiple protein isoforms, the longest consists of 753 amino acids (NM_001128227, NP_001121699, all mutations in this study are described based upon this transcript). 20, 21 The GNE protein contains two functional domains: an N-terminal epimerase domain and a C-terminal kinase domain. 20 It plays a key role in the biosynthesis of N-acetylneuraminic acid, a member of the sialic acid family, which is an important component of cell surface glycoproteins, glycolipids, polysaccharides and gangliosides. These play important roles in cell adhesion and signal transduction. 22 The GNE protein ubiquitously expresses in almost all tissues, 20 with the highest levels in liver and placenta, while relatively low levels in skeletal muscle. It localizes to the cytoplasm, the Golgi-region and the cell nucleus.
1,23
Non-allosteric, homozygous or compound heterozygous, primarily missense mutations in the GNE gene result in reduced GNE epimerase and kinase enzymatic activity. This leads to decreased sialic acid production, which appears to be the main contributor to this still elusive disease pathology. 1 Normal sialylation is crucial to skeletal muscle glycoprotein function. Abnormal glycoprotein sialylation in manifestations. However, the effect of GNE variants on sialylation is unsettled and has yet to be satisfactorily elucidated. 20 In mice, GNE protein expresses at an early embryonic stage and Gne −/− mice is lethal. 4, 24 This is consistent with the lack of biallelic null mutations and only "mildly deleterious" mutations reported in GNE myopathy patients. 4 Given that Gne-deficient hyposialylation is the core pathogenic factor, experimental prophylactic treatments with N-acetylmannosamine or sialic acid metabolites were performed, and effectively avoiding muscle weakness and atrophy in
Gne-deficient mice models were found. [25] [26] [27] [28] This shed a new light on targeted therapy for disease in humans in the near future.
To date, more than 201 GNE mutations across the entire coding region have been reported. They span the epimerase and kinase domains, and allosteric region. (p.D207V) are most common in Japanese patients. 29, 30 This study identifies a homozygous missense mutation, 20 Parental consanguinity was denied by the family, but the mutant allele may originate from a founder as the patients' parents are from the same geographical region.
| CONCLUSIONS
In summary, a homozygous missense mutation c.1627G>A
(p.V543M) in the GNE gene was identified in a Han-Chinese family.
The characteristic clinical manifestations, rimmed vacuoles in muscle biopsies and identification of biallelic GNE mutations, supported a diagnosis of GNE myopathy. 2, 4 To our knowledge, this is the first report of the homozygous c.1627G>A mutation in the GNE gene in patients. Further functional studies and in vitro and/or in vivo models with genetic deficiencies, especially mutant knock-in models are warranted. Future therapeutic strategies might, among other things, focus on metabolic supplementation, better GNE metabolites or sialic acid compounds, medications to block or modify degenerative process, gene or cell-based therapies and the AAV-mediated gene vector for systemic administration of GNE.
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